Stocks of T2 Biosystems Inc. (NASDAQ:TTOO) traded higher last session on Wall Street, down -6.23% to $1.73.
According to the data, T2 Biosystems Inc. (NASDAQ:TTOO) has 3 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $1.50 and a low of $1.50, we find $1.50. Given the previous closing price of $1.85, this indicates a potential downside of -18.92 percent. TTOO stock price is now 6.17% away from the 50-day moving average and -75.56% away from the 200-day moving average. The market capitalization of the company currently stands at $12.35M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A total of 3 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $1.50 as their price target over the next twelve months.
With the price target reduced from $2.60 to $2.40, Alliance Global Partners Downgraded its rating from Buy to Neutral for T2 Biosystems Inc. (NASDAQ: TTOO). On October 08, 2020, BTIG Research recently initiated its ‘Buy’ rating on the stock quoting a target price of $2.50, while ‘Janney’ rates the stock as ‘Neutral’.
In other news, Giffin Brett A., Chief Commercial Officer sold 1,292 shares of the company’s stock on Nov 10. The stock was sold for $2,317 at an average price of $1.79. Upon completion of the transaction, the Chief Commercial Officer now directly owns 2,253 shares in the company, valued at $3897.69. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 08, Chief Financial Officer Sprague John M bought 10,000 shares of the business’s stock. A total of $4,767 was incurred on buying the stock at an average price of $0.48. This leaves the insider owning 152,350 shares of the company worth $0.26 million. Insiders disposed of 362,778 shares of company stock worth roughly $0.63 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in TTOO stock. A new stake in T2 Biosystems Inc. shares was purchased by ALTIUM CAPITAL MANAGEMENT LP during the first quarter worth $98,000. GSA CAPITAL PARTNERS LLP invested $68,000 in shares of TTOO during the first quarter. In the first quarter, JANE STREET GROUP, LLC acquired a new stake in T2 Biosystems Inc. valued at approximately $9,000. SIMPLEX TRADING, LLC acquired a new stake in TTOO for approximately $1,000. In total, there are 70 active investors with 6.80% ownership of the company’s stock.
Tuesday’s opening bell rang with an opening price of $1.8500 for T2 Biosystems Inc. (NASDAQ: TTOO). During the past 12 months, T2 Biosystems Inc. has had a low of $1.05 and a high of $29.25. The fifty day moving average price for TTOO is $1.6294 and a two-hundred day moving average price translates $7.0805 for the stock.
The latest earnings results from T2 Biosystems Inc. (NASDAQ: TTOO) was released for Jun, 2022. According to the Diagnostics & Research Company, earnings per share came in at -$5, missing analysts’ expectations of -$4.5 by -0.5. This compares to -$4.21 EPS in the same period last year. The company reported revenue of $3.68 million for the quarter, compared to $7.43 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -50.5 percent. For the current quarter, analysts expect TTOO to generate $5.9M in revenue.
T2 Biosystems Inc.(TTOO) Company Profile
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
